Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
Allarity Therapeutics (NASDAQ: ALLR) has signed a new commercial agreement with an undisclosed EU-based biotech company for its DRP® platform technology. The agreement includes a non-exclusive global license for selected proprietary Allarity DRP® algorithms in breast cancer and laboratory services from Allarity's Medical Laboratory in Denmark.
The partnership involves advanced transcriptome analysis services to support precision oncology solutions in breast cancer, with committed purchases for laboratory services over the next year. The DRP® platform uses gene expression profiling to predict tumor responses to specific therapies. Allarity currently holds DRPs for over 100 drugs, including both investigational and approved medications.
Allarity Therapeutics (NASDAQ: ALLR) ha stipulato un nuovo accordo commerciale con un'azienda biotecnologica europea non divulgata per la sua tecnologia piattaforma DRP®. L'accordo prevede una licenza globale non esclusiva per specifici algoritmi proprietari Allarity DRP® nel campo del cancro al seno e servizi di laboratorio offerti dal Laboratorio Medico di Allarity in Danimarca.
La collaborazione riguarda servizi avanzati di analisi del trascrittoma per supportare soluzioni di oncologia di precisione nel cancro al seno, con acquisti garantiti di servizi di laboratorio nel corso del prossimo anno. La piattaforma DRP® utilizza il profilo di espressione genica per prevedere la risposta del tumore a terapie specifiche. Allarity detiene attualmente DRP® per oltre 100 farmaci, inclusi sia medicinali in fase di sperimentazione che approvati.
Allarity Therapeutics (NASDAQ: ALLR) ha firmado un nuevo acuerdo comercial con una empresa biotecnológica europea no revelada para su tecnología de plataforma DRP®. El acuerdo incluye una licencia global no exclusiva para algoritmos propietarios seleccionados de Allarity DRP® en cáncer de mama y servicios de laboratorio del Laboratorio Médico de Allarity en Dinamarca.
La colaboración implica servicios avanzados de análisis del transcriptoma para apoyar soluciones de oncología de precisión en cáncer de mama, con compras comprometidas de servicios de laboratorio durante el próximo año. La plataforma DRP® utiliza el perfil de expresión génica para predecir las respuestas tumorales a terapias específicas. Actualmente, Allarity posee DRP® para más de 100 medicamentos, incluidos tanto medicamentos en investigación como aprobados.
Allarity Therapeutics (NASDAQ: ALLR)는 유럽에 기반을 둔 비공개 바이오테크 회사와 DRP® 플랫폼 기술에 관한 새로운 상업적 계약을 체결했습니다. 이 계약은 유방암 분야에서 선택된 Allarity의 독점 DRP® 알고리즘에 대한 비독점 글로벌 라이선스와 덴마크에 위치한 Allarity 의료 실험실의 실험실 서비스 제공을 포함합니다.
이번 파트너십은 유방암 정밀 종양학 솔루션을 지원하기 위한 고급 전사체 분석 서비스를 포함하며, 향후 1년간 실험실 서비스 구매가 약속되어 있습니다. DRP® 플랫폼은 유전자 발현 프로파일링을 사용하여 특정 치료법에 대한 종양 반응을 예측합니다. Allarity는 현재 100개 이상의 약물에 대한 DRP를 보유하고 있으며, 이는 임상 시험 중인 약물과 승인된 약물을 모두 포함합니다.
Allarity Therapeutics (NASDAQ : ALLR) a signé un nouvel accord commercial avec une entreprise biotechnologique européenne non divulguée concernant sa technologie de plateforme DRP®. L'accord comprend une licence mondiale non exclusive pour certains algorithmes propriétaires Allarity DRP® sélectionnés dans le domaine du cancer du sein, ainsi que des services de laboratoire fournis par le laboratoire médical d'Allarity au Danemark.
Le partenariat implique des services avancés d'analyse du transcriptome pour soutenir des solutions d'oncologie de précision dans le cancer du sein, avec des achats engagés de services de laboratoire pour l'année à venir. La plateforme DRP® utilise le profilage de l'expression génique pour prédire les réponses tumorales à des thérapies spécifiques. Allarity détient actuellement des DRP® pour plus de 100 médicaments, incluant à la fois des médicaments en phase d'investigation et approuvés.
Allarity Therapeutics (NASDAQ: ALLR) hat eine neue kommerzielle Vereinbarung mit einem nicht genannten Biotechnologieunternehmen mit Sitz in der EU für seine DRP®-Plattformtechnologie unterzeichnet. Die Vereinbarung umfasst eine nicht-exklusive globale Lizenz für ausgewählte proprietäre Allarity DRP®-Algorithmen im Bereich Brustkrebs sowie Laborleistungen vom medizinischen Labor von Allarity in Dänemark.
Die Partnerschaft beinhaltet fortgeschrittene Transkriptomanalyse-Dienstleistungen, um präzisionsonkologische Lösungen bei Brustkrebs zu unterstützen, mit verbindlichen Bestellungen für Laborleistungen im kommenden Jahr. Die DRP®-Plattform nutzt die Genexpressionsprofilierung, um Tumorreaktionen auf spezifische Therapien vorherzusagen. Allarity besitzt derzeit DRPs für über 100 Medikamente, darunter sowohl experimentelle als auch zugelassene Arzneimittel.
- New commercial agreement validates DRP® technology's broad applicability
- Secured purchase commitments for laboratory services over next year
- Partnership expands awareness of DRP® platform across industry
- Access to global market through non-exclusive licensing deal
- Agreement not expected to have significant financial impact
- Limited to breast cancer applications only
- Non-exclusive nature of the license may limit revenue potential
Insights
Allarity's new licensing deal validates their DRP® technology but has minimal financial impact, serving primarily as strategic positioning.
Allarity Therapeutics has secured a new commercial agreement that provides non-exclusive licensing of their proprietary DRP® algorithms in breast cancer to an undisclosed EU-based biotech company. The agreement also includes laboratory services from Allarity's Danish facility, with purchase commitments extending over the next year for transcriptome analysis services.
While this represents a strategic validation of Allarity's DRP® technology platform, the company explicitly states the deal "is not expected to have a significant impact on the Company's financial outlook." This suggests the monetary value is modest relative to Allarity's overall financial position.
The real significance lies in the technology validation and potential for broader industry adoption. Allarity's DRP® platform, which uses gene expression profiling to predict tumor responses to specific therapies, now gains additional commercial exposure through this partnership. This agreement could serve as a reference case for additional licensing deals, particularly since Allarity holds DRPs for over 100 drugs for research purposes.
Beyond immediate revenue generation, this deal serves three strategic purposes: 1) offset internal operating costs for their laboratory operations, 2) expand industry awareness of their technology platform, and 3) demonstrate commercial viability of their approach to precision oncology. The fact that Allarity can monetize these assets while still focusing on their core stenoparib development program shows management's ability to leverage intellectual property effectively.
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP® algorithms in breast cancer, alongside laboratory services from Allarity’s Medical Laboratory in Denmark.
Under the agreement, Allarity will supply advanced transcriptome analysis services to support the partner’s efforts to deliver precision oncology solutions in breast cancer. The deal also secures purchase commitments for Allarity’s laboratory services over the next year. It is not expected to have a significant impact on the Company’s financial outlook.
“This new agreement is an important validation of the broad applicability of our DRP® technology,” said Thomas Jensen, CEO of Allarity Therapeutics. “Our numerous drug-specific DRPs are built on decades of research and development, and we are pleased to see this work move closer to benefiting more patients in this manner. The agreement also underscores the recognition of our laboratory’s expertise in advanced transcriptomic testing while also offsetting our internal operating costs. We look forward to supporting more partners as they develop precision oncology approaches, further expanding awareness of our DRP® platform across the industry.”
Allarity’s DRP® platform uses advanced gene expression profiling to predict individual tumor responses to specific therapies, aiming to improve patient selection and treatment outcomes. The Company holds DRPs for research use only covering more than 100 drugs, including both investigational compounds and drugs that have obtained marketing approval in various jurisdictions.
About Stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the Company’s clinical development plans for stenoparib; the expected utility and market potential of the DRP® companion diagnostic; and the Company’s broader strategy to secure partnerships and expand laboratory services. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to clinical trial progress and results; regulatory uncertainties; operational challenges in laboratory service delivery; and the Company’s overall financial resources. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
FAQ
What is the new licensing agreement announced by Allarity Therapeutics (NASDAQ: ALLR)?
How many drugs does Allarity's DRP® platform cover?
What is the financial impact of Allarity's new DRP® licensing agreement?
What is Allarity Therapeutics' DRP® platform technology?
What services will Allarity provide under the new agreement?
